EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, CASI Pharmaceuticals's Enterprise Value is $23.17 Mil.
CASI Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-25.28 Mil. Therefore, CASI Pharmaceuticals's EV-to-EBIT for today is -0.92.
The historical rank and industry rank for CASI Pharmaceuticals's EV-to-EBIT or its related term are showing as below:
CASI'
s EV-to-EBIT Range Over the Past 10 Years
Min: -44.66 Med: -5 Max: 0.2
Current: -0.92
During the past 13 years, the highest EV-to-EBIT of CASI Pharmaceuticals was 0.20. The lowest was -44.66. And the median was -5.00.
CASI's EV-to-EBIT is ranked worse than 100% of 444
companies
in the Biotechnology industry
Industry Median: 8.185
vs CASI: -0.92
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. CASI Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $86.26 Mil.
CASI Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-25.28 Mil. CASI Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -29.31%.
CASI Pharmaceuticals EV-to-EBIT Historical Data
The historical data trend for CASI Pharmaceuticals's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CASI Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CASI Pharmaceuticals EV-to-EBIT Distribution
For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where CASI Pharmaceuticals's EV-to-EBIT falls into.
CASI Pharmaceuticals EV-to-EBIT Calculation
CASI Pharmaceuticals's EV-to-EBIT for today is calculated as:
CASI Pharmaceuticals's current Enterprise Value is $23.17 Mil.
CASI Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CASI Pharmaceuticals (NAS:CASI) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
CASI Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2023 was $86.26 Mil.
CASI Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.28 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CASI Pharmaceuticals EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of CASI Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
CASI Pharmaceuticals (CASI Pharmaceuticals) Business Description
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CASI has been successfully added to your 